Federal Circuit Addresses Indefiniteness and Mean-Plus-Function Claiming in Inter Partes Review Proceedings at the PTAB

Feb 13, 2020

Reading Time : 3 min

Prisua Engineering Corp. (“Prisua”) sued Samsung Electronics America, Inc. (“Samsung”) for patent infringement based on Samsung’s “Best Face” feature, which allows taking a burst of pictures and replacing a facial image with a better image in the burst. In response, Samsung petitioned for inter partes review. During review, the Board raised two indefiniteness issues sua sponte that, according to the Board, prevented it from assessing anticipation and obviousness. First, the claims recite “a data entry device … operated by a user to select [] at least one pixel.” Applying IPXL Holdings, LLC v. Amazon.com, Inc., 430 F.3d 1377 (Fed. Cir. 2005), the Board decided that this language was unclear as to whether it covers a device capable of being operated by a user or covers only the user actually operating the device. Second, the claims recite a “digital processing unit,” which the Board interpreted as a means-plus-function term under 35 U.S.C. § 112, ¶ 6, without corresponding structure in the specification.

On appeal, Samsung argued that the Board should have found the claims unpatentable based on indefiniteness in its final written decision. The Federal Circuit disagreed because Congress expressly limited the scope of inter partes review to assessing anticipation and obviousness under 35 U.S.C. §§ 102 and 103 based on patents and printed publications. The court instructed that, if the scope of the claims cannot be ascertained with reasonable certainty for purposes of assessing patentability, the Board should decline to institute the IPR, or if the indefiniteness issue affects only certain claims, the Board should conclude that it could not reach a decision on the merits for those claims. The Federal Circuit stated that, in cases where the Board cannot reach a final decision on certain claims because of indefiniteness, the petitioner would not be estopped by 35 U.S.C. § 315(e) from challenging those claims under §§ 102 and 103 in other proceedings.

Next, the Federal Circuit found that the Board erred in construing “digital processing unit” as a means-plus-function term under 35 U.S.C. § 112, ¶ 6. Because the term does not contain the word “means,” there is a rebuttal presumption that § 112, ¶ 6 does not apply. That presumption may be overcome only if the challenger demonstrates that the claim term fails to “recite sufficiently definite structure” or else recites “function without reciting sufficient structure for performing that function.” The Board, however, pointed to no evidence that a person of skill in the art would regard the term as purely functional. Prisua’s technical expert testified that the term “digital processing unit” is an image processing device that people in the art would be familiar with. Also, the Board treated the term differently in other claims by equating a “digital process unit” to a class of known structures—central processing units. The Federal Circuit found that, as used in the claims, a person of skill would understand the term “digital processing unit” to serve as a stand-in for a general purpose computer or central processing unit, thus a reference to structure. Because the Board erred in applying § 112, ¶ 6, the court rejected the Board’s finding that it could not analyze the claims for anticipation or obviousness.

Lastly, the Federal Circuit addressed the Board’s conclusion that the claims were indefinite under IPXL for reciting both an apparatus and a method of using that apparatus. In light of its decision on the “digital processing unit,” the court decided that the Board ended its analysis with respect to IPXL prematurely. On remand, the Federal Circuit instructed the Board to address Samsung’s argument that the Board may analyze patentability of a claim, even if the claim is indefinite under the reasoning of IPXL. The court limited its decision to only IPXL-type indefiniteness and in forums not authorized to consider indefiniteness as a basis for invalidity, i.e., IPR.

PRACTICE TIP

The Board may not cancel claims for indefiniteness in an IPR. Where claims may be subject to IPXL-type indefiniteness, petitioners should show why they are anticipated or obvious under either interpretation. Also, when seeking to overcome the presumption against applying pre-AIA § 112, ¶ 6 (or AIA § 112(f)) to claim terms that do not recite “means,” challengers should present evidence sufficient to demonstrate that the term fails to “recite sufficiently definite structure” or else recites “function without reciting sufficient structure for performing that function.”

Samsung Electronics America, Inc. v. Prisua Engineering Corp., No. 2019-1169, -1260 (Fed. Cir. Feb. 4, 2020).

Share This Insight

Previous Entries

IP Newsflash

July 11, 2025

The Federal Circuit recently reversed a PTAB determination on remand that a patent was obvious over applicant admitted prior art (“AAPA”) in combination with prior art patents, holding that expressly designating AAPA as a “basis” for a ground is improper under 35 U.S.C. § 311(b). In doing so, the Court rejected the PTAB’s “blanket rule” that “AAPA used in combination with prior art patents or printed publications under § 311(b) is ipso facto not the basis or part of the basis of a ground.” Ultimately, while the case clarifies that expressly listing AAPA in an IPR ground is improper, the precise line between proper and improper uses of AAPA in other instances remains unclear.

...

Read More

IP Newsflash

July 1, 2025

In an appeal from an inter partes review, the Federal Circuit recently clarified that the enablement inquiry applied to prior art references in the context of an anticipation defense differs from the enablement inquiry applied when evaluating the claims of a patent.

...

Read More

IP Newsflash

June 26, 2025

The Northern District of Ohio denied a motion to compel the plaintiff to produce test results referenced in its initial disclosures and complaint. The court found that because the “test results are not facts but rather are opinions,” the information was protected as work product. Furthermore, because that testing would not be used as evidence in the litigation, the defendant was not prejudiced.

...

Read More

IP Newsflash

June 6, 2025

In a precedential opinion, the Federal Circuit definitively held that the Patent Trial and Appeal Board has jurisdiction over IPRs that concern expired patents.

...

Read More

IP Newsflash

June 6, 2025

In a patent infringement litigation in the U.S. District Court for the Eastern District of Texas, Judge Rodney Gilstrap denied a joint motion to stay the litigation pending resolution of inter partes review when it was uncertain that all defendants would be bound by the statutory estoppel provision of 35 U.S.C. § 315(e).

...

Read More

IP Newsflash

May 30, 2025

A district court recently dismissed a patent infringement complaint for improper venue under 28 U.S.C. § 1400(b), finding that the storage and distribution of products from an Amazon warehouse was not sufficient to establish that warehouse as a regular and established place of business in the district.

...

Read More

IP Newsflash

May 27, 2025

The Federal Circuit affirmed a District of Delaware finding of non-infringement in an ANDA litigation due to the patentee’s clear and unmistakable disavowal of claim scope during prosecution. Specifically, the court held that statements made during prosecution of a parent application before the asserted claims were allowed amounted to a prosecution disclaimer that extended to subsequent patents in the family. In reaching this conclusion, the court rejected an attempt by the patentee to resurrect the claim scope through a unilateral, self-serving statement made in later applications in the family.

...

Read More

IP Newsflash

May 13, 2025

The Federal Circuit recently affirmed a district court’s holding that patent term extension (PTE) for a reissued patent was properly based on the issue date of the original patent and not that of the reissued patent. The Federal Circuit concluded that, where both the original and reissued patents claimed a drug product under regulatory review, using the issue date of the original patent to calculate PTE comports with both the purpose of the Hatch-Waxman Act and the related statutory context.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.